New possibilities to control acute exacerbations of chronic obstructive pulmonary disease
https://doi.org/10.18093/0869-0189-2018-28-3-318-324
Abstract
The study was aimed at evaluating efficacy of inhaled combination of hypertonic saline solution and hyaluronic acid in patients with chronic obstructive pulmonary disease (COPD). Methods. Male patients with COPD (n = 99) were involved in the study. Of them, 50 patients were treated with the standard therapy including bronchodilators and mucolytics and 49 patients were treated with bronchodilators and the inhaled combination of 7% hypertonic saline solution and 0.1% solution of hyaluronic acid via a nebulizer, 5 ml b.i.d. during 5 days. Both groups were additionally divided into B, C, and D categories according to severity of symptoms and a rate of exacerbations. The patients were followed-up for 6 months. Clinical and functional parameters including number of exacerbations of COPD and number of hospitalizations were analyzed. Results. Treatment with the inhaled combination of hypertonic saline solution and hyaluronic acid allowed decrease in number of exacerbations of COPD and number of hospitalizations due to exacerbations. Conclusion. The inhaled combination of hypertonic saline solution and hyaluronic acid allowed better control of COPD and could substitute therapeutic bronchoscopy. The combination is well tolerated, has acceptable safety profile without serious adverse events and is convenient to use.
About the Authors
G. L. Ignatova
South Ural State Medical University, Healthcare Ministry of Russia
Russian Federation
Russian Federation
Galina L. Ignatova, Doctor of Medicine, Professor, Head of Department of Therapy, Institute of Postgraduate Physician Training
ul. Vorovskogo 64, Chelyabinsk, 454092
V. N. Antonov
South Ural State Medical University, Healthcare Ministry of Russia
Russian Federation
Russian Federation
Vladimir N. Antonov, Candidate of Medicine, Associate Professor, Department of Therapy, Institute of Postgraduate Physician Training
ul. Vorovskogo 64, Chelyabinsk, 454092
References
1. GOLD 2017. Global initiative for chronic obstructive pulmonary disease. Global strategy for the diagnosis, management, and prevention of COPD. Available at: https://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd/ [Accessed September 18, 2017].
2. Aisanov Z.R., Avdeev S.N., Arkhipov V.V. et al. National Guidelines on Diagnosis and Treatment of Chronic Obstructive Pulmonary Disease: an Algorithm for Making a Clinical Decision. Pul’monologiya. 2017; 27 (1): 13–20. DOI: 10.18093/0869-0189-2017-27-1-13-20 (in Russian).
3. Chikina S.Yu. Mucolytics: a role in the management of patients with chronic obstructive pulmonary disease. Prakticheskaya pul’monologiya. 2015; (4): 18–22. Available at: https://cyberleninka.ru/article/n/mukolitiki-sovremennaya-rol-v-vedenii-bolnyh-hronicheskoy-obstruktivnoy-boleznyu-legkih [Accessed September 18, 2017] (in Russian).
4. Avdeev S.N. A role of mucoactive drugs in treatment of COPD. RMZH «Meditsinskoye obozreniye». 2015; (4): 206–211. Available at: https://www.rmj.ru/articles/pulmonologiya/Znachenie_mukoaktivnyh_preparatov_v_terapii_HOBL/ [Accessed September 18, 2017] (in Russian).
5. Meshcheryakova N.N., Chikina S.Yu. Mucolytic therapy in patients with chronic obstructive pulmonary disease. Consilium Medicum. 2008; 10 (10): 71–75 (in Russian).
6. Lee J.H., Lee Y.K., Kim E.K. et al. Responses to inhaled long-acting beta-agonist and corticosteroid according to COPD subtype. Respir. Med. 2010; 104 (4): 542–549. DOI: 10.1016/j.rmed.2009.10.024.
7. Avdeev S.N. Acute exacerbation of chronic obstructive pulmonary disease. Pul’monologiya. 2014; (6): 65–72. DOI: 10.18093/0869-0189-2014-0-6-65-72 (in Russian).
8. Klyachkina I.L., Sinopal’nikov A.I. Mucoactive drugs. In: Chuchalin A.G., ed. Rational Pharmacotherapy of Respiratory Diseases. Moscow: Litterra; 2013: 103–117 (in Russian).
9. Simonova O.I., Gorinova Yu.V. A new formulation of hypertonic saline solution for inhalations via a nebulizer. Voprosy sovremennoy pediatrii. 2016; 15 (6): 631–634. Available at: https://cyberleninka.ru/article/v/novaya-forma-gipertonicheskogo-rastvora-dlya-nebulayzernoy-terapii [Accessed September 18, 2017] (in Russian).
10. The MRC breathlessness scale. Adapted from: Fletcher C.M. Discussion on the Diagnosis of Pulmonary Emphysema. Proc. R. Soc. Med. 1952; 45 (9): 576–586.
11. St. George’s Hospital Respiratory Questionnaire. Available at: http://www.healthstatus.sgul.ac.uk [Accessed September 18, 2017].
12. Kashirskaya N.Yu., Sherman V.D., Kapranov N.I. et al. A role of hypertonic saline solution in therapy of cystic fibrosis. Pul’monologiya. 2016; 26 (5): 584–590. DOI: 10.18093/0869-0189-2016-26-5-584-590 (in Russian).
13. Bergsson G., Reeves E.P., McNally P. et al. LL-37 complexation with glycosaminoglycans in cystic fibrosis lungs inhibits antimicrobial activity, which can be restored by hypertonic saline. J. Immunol. 2009; 183 (1): 543–551. DOI: 10.4049/jimmunol.0803959.
14. Bucki R., Byfield F.J., Janmey P.A. Release of the antimicrobial peptide LL-37 from DNA/F-actin bundles in cystic fibrosis sputum. Eur. Respir. J. 2007; 29 (4): 624–632. DOI: 10.1183/09031936.00080806.
Review
For citations:
Ignatova G.L., Antonov V.N. New possibilities to control acute exacerbations of chronic obstructive pulmonary disease. PULMONOLOGIYA. 2018;28(3):318-324. (In Russ.) https://doi.org/10.18093/0869-0189-2018-28-3-318-324
Views:
848
Email this article 